Cipla enters respiratory market in Germany and Sweden

02 Sep 2014 Evaluate

Cipla, a global pharmaceutical company, has launched Serroflo, its Salmeterol/Fluticasone MDI, in Germany and Sweden. With this launch, Cipla opens the door for new, highly efficient treatments in the European healthcare market. Serroflo will substantially improve the affordability of Fixed Combinations in Europe and help manage health costs for respiratory treatment.

In Germany the new product is distributed under the name ‘Serroflo’, whereas in Sweden the combination is launched as ‘Salmeterol/Fluticasone Cipla’. Serroflo and Salmeterol/Fluticasone Cipla will be available in a pMDI with HFA propellant in two strengths - 120 doses of 25/125 mcg salmeterol/fluticasone and 120 doses of 25/250 mcg salmeterol/fluticasone.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1494.40 -10.65 (-0.71%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×